RightAnswer Knowledge Solutions Search Results for 56-72-4

New Search  |  Search Results (56-72-4)  |  Index of Example Chemical Results Pages
register now
RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.

A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
  • Chemical Identification
  • Environmental Hazards
  • First Aid/Medical Treatment
  • Handling/Storage/Shipping/Waste Management
  • Personal Protection
  • Physical Hazards/Corrective Response Actions
  • Physical/Chemical Properties
  • Regulatory/Standards/Labels
  • Report Abstracts and Studies
  • Reproductive Risk
  • Toxicology/Health Hazards/Exposure
Example of Acute Exposure data from MEDITEXT.

RightAnswer Proprietary Data Sources:

HAZARDTEXT™ Documentshelp
MEDITEXT® Documentshelp
REPROTEXT® Documentshelp


All Other Data Sources:

CCRIS Documentshelp
CHRIS Documentshelp
DART Documentshelp
ECOTOX Documentshelp
GENE-TOX Documentshelp
HSDB® Data Bankhelp
LOLI® Listingshelp
New Jersey Fact Sheetshelp
NTP - Long-Term Studieshelp
OHM/TADS Documentshelp
RTECS® Registryhelp
Shepard's Cataloghelp
MSDSonline®help

ChemID External Links:

EPA Envirofactshelp
Coumaphos [ISO]
EPA SRShelp
Coumaphos [ISO]
EXTOXNEThelp
Coumaphos [ISO]
MeSHhelp
Coumaphos [ISO]
MeSH Headinghelp
Coumaphos [ISO]
NIAID ChemDBhelp
Coumaphos [ISO]
NIOSH ICSChelp
Coumaphos [ISO]
NIST WebBookhelp
Coumaphos [ISO]
OSHA Chemhelp
Coumaphos [ISO]
PestNamehelp
Coumaphos [ISO]
PubChemhelp
Coumaphos [ISO]
PubMedhelp
Coumaphos [ISO]
PubMed Cancerhelp
Coumaphos [ISO]
PubMed Toxicologyhelp
Coumaphos [ISO]
SRC CHEMFATEhelp
Coumaphos [ISO]
SRC DATALOGhelp
Coumaphos [ISO]
TOXLINEhelp
Coumaphos [ISO]
TOXMAPhelp
Coumaphos [ISO]

Other Government Links Searched via RegsKnowledge:

State Environmental Regulationshelp
CFR Regulationshelp

Example Content from MEDITEXT for 56-72-4:


Please note: this is an extract of information from a larger document. Full document and details are available by subscription.

ACUTE EXPOSURE INFORMATION

  1. The following are symptoms due to organophosphates in general, which are due to the anticholinesterase activity of this class of compounds. All of these effects may not be documented for coumaphos, but could potentially occur in individual cases.
  1. USES: Coumaphos, an organophosphate compound, is registered for use as an insecticide in the United States. It may also be available in other countries.
  1. TOXICOLOGY: Organophosphates competitively inhibit pseudocholinesterase and acetylcholinesterase, preventing the hydrolysis and inactivation of acetylcholine. Acetylcholine accumulates at nerve junctions, causing malfunction of the sympathetic, parasympathetic, and peripheral nervous systems and some of the CNS. Clinical signs of cholinergic excess can develop.
  1. EPIDEMIOLOGY: Exposure to organophosphates is common, but serious toxicity is unusual in the US. Common source of severe poisoning in developing countries.
  1. WITH POISONING/EXPOSURE
    1. MILD TO MODERATE POISONING: MUSCARINIC EFFECTS: Can include bradycardia, salivation, lacrimation, diaphoresis, vomiting, diarrhea, urination, and miosis. NICOTINIC EFFECTS: Tachycardia, hypertension, mydriasis, and muscle cramps.
    1. SEVERE POISONING: MUSCARINIC EFFECTS: Bronchorrhea, bronchospasm, and acute lung injury. NICOTINIC EFFECTS: Muscle fasciculations, weakness, and respiratory failure. CENTRAL EFFECTS: CNS depression, agitation, confusion, delirium, coma, and seizures. Hypotension, ventricular dysrhythmias, metabolic acidosis, pancreatitis, and hyperglycemia can also develop.
    1. DELAYED EFFECTS: Intermediate syndrome is characterized by paralysis of respiratory, cranial motor, neck flexor, and proximal limb muscles 1 to 4 days after apparent recovery from cholinergic toxicity, and prior to the development of delayed peripheral neuropathy. Manifestations can include the inability to lift the neck or sit up, ophthalmoparesis, slow eye movements, facial weakness, difficulty swallowing, limb weakness (primarily proximal), areflexia, and respiratory paralysis. Recovery begins 5 to 15 days after onset. Distal sensory-motor polyneuropathy may rarely develop 6 to 21 days following exposure to some organophosphate compounds, however, it has not yet been reported in humans after exposure to coumaphos. Characterized by burning or tingling followed by weakness beginning in the legs which then spreads proximally. In severe cases, it may result in spasticity or flaccidity. Recovery requires months and may not be complete.
    1. CHILDREN: May have different predominant signs and symptoms than adults (more likely CNS depression, stupor, coma, flaccidity, dyspnea, and seizures). Children may also have fewer muscarinic and nicotinic signs of intoxication (ie, secretions, bradycardia, fasciculations and miosis) as compared to adults.
    1. INHALATION EXPOSURE: Organophosphate vapors rapidly produce mucous membrane and upper airway irritation and bronchospasm, followed by systemic muscarinic, nicotinic and central effects if exposed to significant concentrations.
© 2011-2017 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.